Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 2
1991 1
1993 1
1997 2
1998 1
1999 1
2000 2
2001 1
2003 2
2004 3
2005 1
2006 1
2011 1
2012 1
2013 1
2016 2
2017 4
2018 5
2019 2
2020 2
2021 1
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

38 results
Results by year
Filters applied: . Clear all
Page 1
An immunogenic personal neoantigen vaccine for patients with melanoma.
Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ. Ott PA, et al. Among authors: daley h. Nature. 2017 Jul 13;547(7662):217-221. doi: 10.1038/nature22991. Epub 2017 Jul 5. Nature. 2017. PMID: 28678778 Free PMC article. Clinical Trial.
Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease.
Esrick EB, Lehmann LE, Biffi A, Achebe M, Brendel C, Ciuculescu MF, Daley H, MacKinnon B, Morris E, Federico A, Abriss D, Boardman K, Khelladi R, Shaw K, Negre H, Negre O, Nikiforow S, Ritz J, Pai SY, London WB, Dansereau C, Heeney MM, Armant M, Manis JP, Williams DA. Esrick EB, et al. Among authors: daley h. N Engl J Med. 2021 Jan 21;384(3):205-215. doi: 10.1056/NEJMoa2029392. Epub 2020 Dec 5. N Engl J Med. 2021. PMID: 33283990 Free PMC article. Clinical Trial.
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.
Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, Shukla SA, Hu Z, Li L, Le PM, Allesøe RL, Richman AR, Kowalczyk MS, Abdelrahman S, Geduldig JE, Charbonneau S, Pelton K, Iorgulescu JB, Elagina L, Zhang W, Olive O, McCluskey C, Olsen LR, Stevens J, Lane WJ, Salazar AM, Daley H, Wen PY, Chiocca EA, Harden M, Lennon NJ, Gabriel S, Getz G, Lander ES, Regev A, Ritz J, Neuberg D, Rodig SJ, Ligon KL, Suvà ML, Wucherpfennig KW, Hacohen N, Fritsch EF, Livak KJ, Ott PA, Wu CJ, Reardon DA. Keskin DB, et al. Among authors: daley h. Nature. 2019 Jan;565(7738):234-239. doi: 10.1038/s41586-018-0792-9. Epub 2018 Dec 19. Nature. 2019. PMID: 30568305 Free PMC article. Clinical Trial.
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.
Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, Schmucker A, Reder J, Sentman CL, Gilham DE, Lehmann FF, Galinsky I, DiPietro H, Cummings K, Munshi NC, Stone RM, Neuberg DS, Soiffer R, Dranoff G, Ritz J, Nikiforow S. Baumeister SH, et al. Among authors: daley h. Cancer Immunol Res. 2019 Jan;7(1):100-112. doi: 10.1158/2326-6066.CIR-18-0307. Epub 2018 Nov 5. Cancer Immunol Res. 2019. PMID: 30396908 Free PMC article. Clinical Trial.
Ethambutol in tuberculosis: time to reconsider?
Graham SM, Daley HM, Banerjee A, Salaniponi FM, Harries AD. Graham SM, et al. Among authors: daley hm. Arch Dis Child. 1998 Sep;79(3):274-8. doi: 10.1136/adc.79.3.274. Arch Dis Child. 1998. PMID: 9875029 Free PMC article. Review. No abstract available.
GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial.
Ho VT, Kim HT, Brock J, Galinsky I, Daley H, Reynolds C, Weber A, Pozdnyakova O, Severgnini M, Nikiforow S, Cutler C, Koreth J, Alyea EP, Antin JH, Gooptu M, Romee R, Shapiro R, Chen YB, Rosenblatt J, Avigan D, Hodi FS, Dranoff G, Wu CJ, Ritz J, Soiffer RJ. Ho VT, et al. Among authors: daley h. Blood Adv. 2022 Apr 12;6(7):2183-2194. doi: 10.1182/bloodadvances.2021006255. Blood Adv. 2022. PMID: 34807983 Free PMC article. Clinical Trial.
Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma.
Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ. Ott PA, et al. Among authors: daley h. Nature. 2018 Mar 14;555(7696):402. doi: 10.1038/nature25145. Nature. 2018. PMID: 29542692 Free PMC article.
Dangerous repairs.
Daley H, Amoroso P. Daley H, et al. Anaesthesia. 1991 Nov;46(11):997. doi: 10.1111/j.1365-2044.1991.tb09897.x. Anaesthesia. 1991. PMID: 1750624 Free article. No abstract available.
Phase 1 Study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.
Frigault MJ, Bishop MR, Rosenblatt J, O'Donnell E, Raje N, Cook D, Yee AJ, Logan E, Avigan D, Jakubowiak AJ, Shaw KL, Daley H, Nikiforow S, Griffin FM, Cornwell C, Shen A, Heery C, Maus MV. Frigault MJ, et al. Among authors: daley h. Blood Adv. 2022 Apr 25:bloodadvances.2022007210. doi: 10.1182/bloodadvances.2022007210. Online ahead of print. Blood Adv. 2022. PMID: 35468618
38 results